Xconomy | San Diego - Business + Technology in the Exponential Economy

Cadence Shares Boom as IV Pain Reliever Reaches Goal in Study
Cadence, Aiming to Reduce Narcotics Use in Hospitals, Gears Up to Market IV Pain Reliever
Cadence Drug Fails to Prevent Hospital Infections; Company Scraps Program
Cadence Turns Attention to Marketplace, as IV Pain Reliever Reaches Goals in Clinical Trials
Intellikine Raises $28.5M, Cadence Awaits FDA Action, Somaxon Seeks FDA Approval Again for Insomnia Drug, & More San Diego Life Sciences News

Cadence Applies for FDA Approval

Cadence Pharmaceuticals (NASDAQ: CADX), the San Diego-based developer of a new pain medication, said today it has filed an application to seek FDA approval to start selling it in the U.S. The drug, an intravenous form of acetaminophen with the trade name of Acetavance, reached its goal of providing pain relief in a clinical trial. If approved, it would be the first new IV pain reliever approved in the U.S. in more than 20 years, the company said.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: